3rd Liquid Biopsy Surveillance Summit

Conference themes
Liquid biopsies are revolutionizing clinical trials, emerging as a game-changing diagnostic tool for monitoring molecular residual disease and detecting disease resistance. This breakthrough enables precise patient stratification, ensuring they receive the most effective and safe treatments. In 2024, a wave of collaborations has surged, propelling the use of liquid biopsies for MRD testing to new heights.

Scientific Society
Hanson Wade

Notes
Brochure: https://go.evvnt.com/2612043-3?pid=4832

Speakers: Angela Silvestro, Director - Companion Diagnostics, GSK, David Yu, Director - Precision Medicine and Translational Medicine, Bristol Myers Squibb and more

https://go.evvnt.com/2612043-2?pid=4832

Ms. Stacey Millard